Education

Key Considerations: Advances in Gene Therapy for Hemophilia ENDURING

2020 Virtual Learning Sessions

Presented by Glenn Pierce, MD, PhD, Lindsey George, MD, Alfonso Iorio, MD, Barbara Konkle, MD

EAHAD Gene Therapy Working Group

Podcasts

Presented by Wolfgang Miesbach, MD

ISTH Gene Therapy for Hemophilia Initiative and the Role of EAHAD

Podcasts

Presented by Flora Peyvandi, MD, PhD

History of EAHAD and the Upcoming Congress

Podcasts

Presented by Aislin Ryan, the CEO of EAHAD

Hemophilia Gene Therapy: Expectations for Reliability and Accessibility

Podcasts

Presented by Andrew Leavitt, MD

First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A – BAY 2599023 has Broad Patient Eligibility and Stable and Sustained Long-Term Expression of FVIII

Conference Coverage

Steven W. Pipe, MD

Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults With Severe or Moderate-Severe Hemophilia B: Two Year Data From a Phase 2b Trial

Conference Coverage

Steven W. Pipe, MD 

First Data From the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults With Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing

Conference Coverage

Steven W. Pipe, MD

AMT-060 Gene Therapy in Adults With Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for Up to 5 Years

Conference Coverage

Wolfgang A. Miesbach, MD

Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults With Severe Hemophilia

Conference Coverage

Barbara A. Konkle, MD

Latest Advances in Gene Therapy for Hemophilia in Portuguese

Podcasts

Presented by Margareth Ozelo, MD, PhD

Obstacles and Opportunities

Interactive Webinars

Presented by Frank W.G. Leebeek, MD, PhD

Key Considerations: Advances in Gene Therapy for Hemophilia

2020 Virtual Learning Sessions

Presented by Glenn Pierce, MD, PhD, Lindsey George, MD, Alfonso Iorio, MD, Barbara Konkle, MD

The Safety of Hemophilia Gene Therapy Now and in the Future

Podcasts

Presented by Michael Makris, MA, MB BS, MD, FRCP, FRCPath

Lentivirus Vectors for Hemophilia Gene Therapy

Podcasts

Presented by Glenn F. Pierce, MD, PhD and Robert Peters, PhD

WFH Gene Therapy Registry

Podcasts

Presented by Barbara A. Konkle, MD and Johnny Mahlangu, BSc, MBBCh, MMed, FCPath

Stepping Into the Future: Hemophilia Gene Therapy Clinical Trial Updates

2020 Virtual Learning Sessions

Presented by Flora Peyvandi, MD, PhD, Glenn Pierce, MD, PhD, and Steven W. Pipe, MD

Patient Support, Patient Counseling, and Monitoring

Interactive Webinars

Presented by Lindsey A. George, MD

Gene Therapy for FVIII

Interactive Webinars

Presented by K. John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPC

Learning from Clinical Trials and Preparing for Clinical Practice

2020 Virtual Learning Sessions

Presented by Steven W. Pipe, MD and Guy Young, MD

HTC Readiness: A Multidisciplinary Perspective

Podcasts

Presented by Steven W. Pipe, MD and Debra Pollard, RN

HTC Readiness: A Global Perspective

Podcasts

Presented by Steven W. Pipe, MD and Debra Pollard, RN

Frequency, Location and Nature of AAV Vector Insertions After Long-term Follow-up of FVIII Transgene Delivery in a Hemophilia A Dog Model

Conference Coverage

Paul Batty, MBBS, PhD 

A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)

Conference Coverage

Pratima Chowdary, MRCP, FRCPath

Subcategories

Interactive Webinars

2020 Virtual Learning Sessions